



**World Health  
Organization**

**WHO/BS/2018.2352  
ENGLISH ONLY**

**EXPERT COMMITTEE ON BIOLOGICAL STANDARDIZATION**  
**Geneva, 29 October to 2 November 2018**

**WHO Questions and Answers: Similar Biotherapeutic Products**

Proposed document to complement the WHO guidelines on evaluation of similar biotherapeutic products, Annex 2, WHO TRS No. 977, adopted in 2009

NOTE:

This draft document has been prepared for the purpose of inviting comments and suggestions on the proposals contained therein, which will then be considered by the WHO Expert Committee on Biological Standardization (ECBS). The distribution of this document is intended to bring the proposed WHO document on *Questions and Answers on similar biotherapeutic products* to the attention of a broad audience and to improve the transparency of the consultation process.

**The text in its present form does not necessarily represent an agreed formulation of the ECBS. Written comments proposing modifications to this text MUST be received by 20 September 2018 using the Comment Form available separately** and should be addressed to: Department of Essential Medicines and Health Products (EMP), World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland. Comments may also be submitted electronically to the Responsible Officer: Dr Hye-Na Kang at [kangh@who.int](mailto:kangh@who.int).

The outcome of the deliberations of the ECBS will be published in the WHO Technical Report Series. The final agreed formulation of the document will be edited to be in conformity with the second edition of the *WHO style guide* (KMS/WHP/13.1).

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37

© World Health Organization 2018

All rights reserved.

This draft is intended for a restricted audience only, i.e. the individuals and organizations having received this draft. The draft may not be reviewed, abstracted, quoted, reproduced, transmitted, distributed, translated or adapted, in part or in whole, in any form or by any means outside these individuals and organizations (including the organizations' concerned staff and member organizations) without the permission of the World Health Organization. The draft should not be displayed on any website.

Please send any request for permission to:


Dr Ivana Knezevic, Technologies Standards and Norms, Department of Essential Medicines and Health Products, World Health Organization, CH-1211 Geneva 27, Switzerland. Email: [knezevici@who.int](mailto:knezevici@who.int).

The designations employed and the presentation of the material in this draft do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by the World Health Organization to verify the information contained in this draft. However, the printed material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.

This draft does not necessarily represent the decisions or the stated policy of the World Health Organization.



## WHO Questions and Answers: Similar Biotherapeutic Products

### Background

#### **I. Concept for licensing similar biotherapeutic products**

- 1  
2
- 3  
4
- 5  
6 QI-1 What is a similar biotherapeutic product (SBP)?
- 7 QI-2 How are SBPs evaluated for licensing?
- 8 QI-3 What are the differences between SBPs and generic products?
- 9 QI-4 Which products can be approved as SBPs?
- 10

#### **II. Reference biotherapeutic products**

- 11  
12 QII-1 What is the reference biotherapeutic product (RBP) mentioned in the biosimilar  
13 regulatory framework?
- 14 QII-2 What are the criteria for selection of an RBP?
- 15 QII-3 Under what circumstances would it be acceptable to use a foreign-sourced RBP?
- 16 QII-4 Can the SBP be approved when compared with an RBP which is not available in  
17 the domestic market?
- 18 QII-5 The guidelines state that “the same RBP should be used throughout the entire  
19 comparability exercise”. Can an RBP from another manufacturing site be used?
- 20

#### **III. Quality**

- 21  
22 QIII-1 Should the expression system used in producing an SBP be the same as the one  
23 used to produce the RBP?
- 24 QIII-2 Should the SBP have the same formulation as the RBP?
- 25 QIII-3 Should the SBP have the same delivery device or container closure system as the  
26 RBP?
- 27 QIII-4 Should the SBP have the same strength as the RBP and how can this be  
28 demonstrated?
- 29 QIII-5 Should the specifications of the SBP be the same as those of the RBP?
- 30 QIII-6 How many batches must be analysed in the comprehensive comparability studies?
- 31 QIII-7 What is the role of pharmacopoeial monographs in the evaluation of SBPs?
- 32 QIII-8 What is the role of reference standard materials in the evaluation of SBPs?
- 33 QIII-9 How should the expiry date of an SBP be established?
- 34 QIII-10 Are comparability studies in accelerated and stress stability tests needed?
- 35 QIII-11 When conducting a comparability exercise, head-to-head characterization studies  
36 are required to compare the SBP and the RBP. How much difference or what kinds  
37 of differences can be accepted while ensuring a high degree of similarity between  
38 the SBP and the RBP?

1 QIII-12 How comprehensive should the evaluation of glycan structure (i.e. level of details)  
2 be?

3 QIII-13 How can statistical analysis support the demonstration of similarity of an SBP to  
4 the RBP in quality evaluation?

5

6 **IV. Nonclinical evaluation**

7 QIV-1 Which general factors should be considered for the planning/conduct of the  
8 nonclinical studies for an SBP?

9

10 Nonclinical in vitro studies

11 QIV-2 What kind of in vitro studies should be conducted for the nonclinical evaluation of  
12 an SBP?

13 QIV-3 Which specific factors should be observed for the planning/conduct of the  
14 nonclinical in vitro studies?

15

16 Nonclinical in vivo studies

17 QIV-4 Which factors should be considered when deciding whether in vivo animal studies  
18 are required for nonclinical evaluation of a specific SBP?

19 QIV-5 Which specific factors should be considered in the planning/conduct of in vivo  
20 animal studies on pharmacodynamics and/or pharmacokinetics of an SBP?

21 QIV-6 Which specific factors should be considered in the planning/conduct of in vivo  
22 animal toxicity studies for an SBP?

23 QIV-7 Where no suitable animal model is available, how can the nonclinical  
24 comparability exercise be extended?

25 QIV-8 Under what circumstances/conditions would additional in vivo nonclinical  
26 comparability studies be required?

27

28 **V. Clinical evaluation**

29 QV-1 What is the role of clinical evaluation in the SBP development?

30 QV-2 What is immunogenicity and which factors should be considered in terms of  
31 immunogenicity for an SBP?

32 QV-3 What duration of immunogenicity is required in the clinical studies?

33 QV-4 How are differences in immunogenicity handled?

34 QV-5 If the RBP shows a higher rate of anti-drug antibodies than the historical data, what  
35 would be the data requirement for the SBP?

36 QV-6 If the comparability study of efficacy is waived, is a separate immunogenicity  
37 study required or could immunogenicity assessment be conducted in a comparative  
38 pharmacokinetic/pharmacodynamic study?

39 QV-7 How can SBPs be approved for indications for which no clinical studies have been  
40 conducted?

41 QV-8 What are the most important “points to consider” in extrapolating clinical data  
42 showing biosimilarity in one indication to other licensed indications of the RBP?

- 1 QV-9 After an SBP has been approved, can a new indication added to the RBP be shared  
2 with the SBP?
- 3 QV-10 Why are different regulatory decisions on extrapolation reached by different  
4 national regulatory authorities (NRA) when using the same regulatory data  
5 package?
- 6 QV-11 How should inexperienced NRAs deal with differing regulatory decisions of major  
7 experienced NRAs?
- 8 QV-12 Is there always a need to conduct a clinical study for an SBP?

9

## 10 **VI. Pharmacovigilance:**

- 11 QVI-1 Will SBPs be as safe as originator products?
- 12 QVI-2 After an SBP has been approved, is the SBP required to show the maintenance of  
13 biosimilarity with its RBP?
- 14 QVI-3 Would it be beneficial to review/discuss post-marketing commitments from each  
15 NRA after extrapolation of indications?
- 16 QVI-4 If safety information of the RBP (i.e.as the result of adverse events) is amended,  
17 how would it be applied to SBPs that are already approved?
- 18 QVI-5 Can the SBP marketing authorization holder seek approval for a new indication,  
19 dosage form or route of administration that is different from the RBP?
- 20 QVI-6 Should cautions for the use of an SBP be the same with those for the licensed RBP?

21

## 22 **Authors and acknowledgements**

## 23 **Other recommended reading**

24

25

26

27 Guidance documents published by the World Health Organization (WHO) are intended to be scientific and advisory in nature. Each of the following sections constitutes guidance for national regulatory authorities (NRA) and for manufacturers of biological products.

1 **Abbreviations**

2

3 ADA anti-drug antibody

4 ADCC antibody-dependent cellular cytotoxicity

5 ADCP antibody-dependent cellular phagocytosis

6 CDC complement-dependent cytotoxicity

7 ECBS Expert Committee on Biological Standardization

8 EU European Union

9 FDA (United States) Food and Drug Administration

10 NRA national regulatory authority

11 PD pharmacodynamics

12 PK pharmacokinetics

13 Q&A questions and answers

14 RBP reference biotherapeutic product

15 SBP similar biotherapeutic product

16 WHO World Health Organization

17

DRAFT

## 1 Background

2 WHO's *Guidelines on evaluation of similar biotherapeutic products (SBPs)* (also called  
3 "biosimilars"), adopted by the WHO Expert Committee on Biological Standardization  
4 (ECBS) in 2009, have raised awareness of the complex scientific issues related to the  
5 licensing of SBPs. However, in some countries and for a variety of reasons, biotherapeutic  
6 products have been licensed as generics or as small molecule drugs using data which do not  
7 now meet current WHO regulatory expectations. Very little is known about the safety and  
8 efficacy of these individual products. Consequently, these products need to be reassessed by  
9 national regulatory authorities (NRAs), as described in the WHO guidance document on  
10 *Regulatory assessment of approved rDNA-derived biotherapeutics*.

11 In May 2014, the Sixty-seventh World Health Assembly adopted a new resolution on access  
12 to biotherapeutic products while ensuring their quality, safety and efficacy. One of the  
13 requests was for the WHO ECBS "to update the 2009 guidelines, taking into account the  
14 technological advances for the characterization of biotherapeutic products and considering  
15 national regulatory needs and capacities".

16 In response, WHO has convened meetings to identify the needs, as well as the parts of the  
17 guidelines which should be updated. In April 2015, an informal consultation was organized  
18 on the possible amendment of the guidelines. All participants from NRAs from both  
19 developing and developed countries, as well as those from industry, recognized and agreed  
20 that the evaluation principles described in WHO's 2009 *Guidelines on evaluation of similar  
21 biotherapeutic products (SBPs)* were still valid, valuable and applicable in facilitating the  
22 harmonization of SBP requirements globally. It was therefore concluded that there was no  
23 need to revise the main body of the existing guidelines on SBPs. However, it was also agreed  
24 that there was a need for additional guidance on the evaluation of monoclonal antibody  
25 products as biosimilars, and this guidance was subsequently developed and was adopted by  
26 the ECBS 2016. In May 2017, WHO held another consultation on improving access to and  
27 use of similar biotherapeutic products. From the outcome of this consultation, WHO noted  
28 that developing a questions and answers (Q&As) document is more appropriate than revision  
29 of the guidance content for further clarifying and complementing some areas and points  
30 written in the guidelines.

31 These Q&As are produced for guidance only and should be read in conjunction with relevant  
32 WHO guidelines. The Q&As are intended to provide clarity to questions that may arise in the  
33 use of WHO guidelines. The questions in this document have been selected on the basis of  
34 those frequently asked by regulators during the implementation workshops on WHO's  
35 *Guidelines on evaluation of similar biotherapeutic products (SBPs)* in the past 8 years. The  
36 intention is to update the Q&As regularly to reflect new developments and issues that arise,  
37 but not to address issues of interchangeability, switching, substitution, naming or shortages  
38 which are out of the scope of the original guidelines.

39

## **I. Concept for licensing similar biotherapeutic products:**

### **QI-1 What is a similar biotherapeutic product (SBP)?**

According to WHO's *Guidelines on evaluation of similar biotherapeutic products (SBPs)*, an SBP is a biotherapeutic product which is similar in terms of quality, safety and efficacy to an already licensed reference biotherapeutic product (RBP).

In addition to "SBP", a variety of terms – such as "similar biological medicinal products", "biosimilar products", "follow-on protein products" and "subsequent-entry biologics" – have been used to describe these products. Since the main principles of developing SBPs are the same, definitions of the SBP are complementary to the WHO definition. For example, in the European Union (EU), a biosimilar must be highly similar to its RBP. High similarity means that the characteristics of quality, biological activity, safety and efficacy of the SBP and its RBP have been shown to be comparable to the degree that the drug substance of the SBP can be called a version of the drug substance of the RBP.

According to the definition of the United States Food and Drug Administration (FDA), there may be differences between the clinically inactive parts of the SBP and the RBP. However, there should be no clinically meaningful differences in the safety, purity and potency of the product.

Based on the above definitions, an SBP is highly similar to an original biotherapeutic product (i.e. RBP) and has been developed and assessed according to the regulatory guidelines that ensure an adequate comparison of the SBP to its RBP.

A medicinal product that has not been compared and shown to be similar to a reference product as indicated in the WHO SBP guidelines should not be called "similar" or SBP (see also the WHO guidance document on *Regulatory assessment of approved rDNA-derived biotherapeutics*).

### **QI-2 How are SBPs evaluated?**

The development and evaluation principles for SBPs and products containing new active substances, such as RBPs, are different. The RBP of an SBP has been licensed on the basis of a full registration dossier of the pharmaceutical quality, pharmacology and toxicology, as well as of human safety and efficacy, in its therapeutic indications.

The development of SBPs relies not only on producing a product that meets the same quality requirements as any other biotherapeutic, but also on generating additional comparative analytical and functional data showing high similarity to the RBP and allowing subsequent abbreviation of the nonclinical and clinical development. This is possible when the manufacturer can demonstrate that the active substances of the SBP and the RBP are highly similar and, thus, can be expected to have the same quality, safety and efficacy. This is achieved by a comprehensive head-to-head analytical comparison of the SBP and the RBP;



1 these data have to be included and submitted in addition to the pharmaceutical quality part of  
2 the SBP. Once the analytical similarity has been established, the nonclinical and clinical  
3 studies may be abbreviated and/or refined. The role of the nonclinical and clinical study  
4 programme is only confirmatory because the aim of the nonclinical and clinical studies is to  
5 demonstrate comparability between the SBP and RBP and not to demonstrate efficacy per se.

6 The extent of the (non)clinical programme depends on the ability to demonstrate structural  
7 and functional similarity between the SBP and its RBP. Thus, the development should be a  
8 stepwise approach in which the results of the previous tests and studies will guide the next  
9 steps. Extensive comparisons will inevitably reveal some differences that may be real, or may  
10 just reflect limitations of the analytical/assay methods used. Therefore, the overall assessment  
11 of similarity is based on the evaluation of the whole comparability data package consisting of  
12 quality, nonclinical and clinical data (also called “totality of evidence”).

13 The quality and function of a biotherapeutic product are highly dependent on its  
14 manufacturing process. The manufacturing process of a biotherapeutic product, both SBPs  
15 and RBPs, is changed several times during its life cycle. Significant changes may have an  
16 impact on the product. Therefore, regulatory authorities will require the manufacturer to  
17 demonstrate with appropriate tests that the safety and efficacy of the product has not been  
18 changed. The requirements of these comparability studies after a manufacturing change are  
19 described in WHO’s *Guidelines on procedures and data requirements for changes to*  
20 *approved biotherapeutic products*.

21 Comparability studies may include physico-chemical and structural analyses as well as in  
22 vitro functional, often cell-based, tests. For more extensive changes and changes that may  
23 have a potential clinical impact, additional nonclinical and clinical studies may be required.  
24 Regulators have gained experience over many years of assessing manufacturer changes made  
25 to the manufacturing process for numerous biotherapeutics to ensure that the safety and  
26 efficacy of the product pre- and post-change is comparable. This experience has enabled the  
27 development of the concept of biosimilarity.

28 The general scientific principles of comparability assessment for manufacturing changes are  
29 applicable to an assessment of similarity for SBPs. The demonstration of high similarity is  
30 based on an extensive head-to-head comparability exercise consisting of comparative state-  
31 of-the-art physico-chemical, structural and in vitro functional tests, as well as nonclinical and  
32 clinical studies. The clinical experience and established safety profile of the originator  
33 products facilitates the development of SBPs.

### 34 35 **QI-3 What are the differences between SBPs and generic products?**

36 The term “generic” medicine is used to describe chemical, small molecule medicinal products  
37 that are structurally and therapeutically equivalent to an originator product of which the  
38 patent and/or data protection period has expired. In contrast, SBPs refer to relatively large  
39 and complex molecules of biological origin which are difficult to characterize. The  
40 abbreviated development of both generics and SBPs depends on the data of their reference  
41 products.

1 The demonstration of structural identity and bioequivalence of a generic medicine to the  
2 reference product is usually sufficient for the licensing of the generic medicine. However, the  
3 approach established for licensing generic medicines through bioequivalent studies alone is  
4 not scientifically appropriate for licensing an SBP which requires much more extensive  
5 studies. Additional analytical and functional, as well as nonclinical and clinical, studies are  
6 needed to demonstrate similarity between an SBP and the RBP. SBPs and RBPs are usually  
7 produced in cells that generate a product with some microheterogeneity that is unique to each  
8 cell type and manufacturing process. Therefore, SBPs and RBPs, or any other therapeutic  
9 protein and their versions after a change in manufacturing process, cannot be shown to be  
10 identical.

11 In some countries, for various reasons, biotherapeutic products were licensed as generics or  
12 as small molecule drugs using data that do not meet current WHO regulatory expectations.  
13 Often little is known about the safety and efficacy of the individual products. These products  
14 need to be reassessed by NRAs) as described in the WHO guidance document on *Regulatory*  
15 *assessment of approved rDNA-derived biotherapeutics*.

16

#### 17 **QI-4 Which products can be approved as SBPs?**

18 SBPs should be developed and evaluated according to WHO's *Guidelines on evaluation of*  
19 *similar biotherapeutic products (SBPs)* or similar national guidelines. The RBP must have  
20 been licensed on the basis of full data on quality, safety and efficacy.

21 The development of an SBP to a licensed original biotherapeutic product (i.e. RBP) depends  
22 on the ability to characterize and compare their structure and function. To date, SBPs have  
23 been developed for well-established and well-characterized biotherapeutic products, such as  
24 recombinant DNA-derived therapeutic proteins with a proven record of clinical safety and  
25 efficacy. Vaccines, plasma-derived products and their recombinant analogues are beyond the  
26 scope of the WHO guidelines on SBPs as recommended the WHO ECBS in 2008. However,  
27 biosimilar versions of low-molecular-weight heparins, although not proteins, have been  
28 licensed in some jurisdictions as SBPs.

29

## **II. Reference biotherapeutic products:**

### **QII-1 What is the reference biotherapeutic product (RBP) referred to in the biosimilar regulatory framework?**

An RBP is the comparator for head-to-head comparability studies with the SBP in order to show similarity in terms of quality, safety and efficacy. Only an originator product that was licensed in accordance with WHO's *Guidelines on the quality, safety and efficacy of biotherapeutic protein products prepared by recombinant DNA technology* on the basis of a stand-alone registration dossier can serve as an RBP. The term does not refer to measurement standards such as international, pharmacopoeial or national standards or reference standards. A manufacturer developing an SBP may be allowed to reduce the nonclinical and clinical data set required for licensure if the similarity of the SBP to the chosen RBP in terms of quality is demonstrated by appropriate comparability studies.

### **QII-2 What are the criteria for selection of an RBP?**

The main criteria for the selection of the RBP are mentioned in WHO's *Guidelines on evaluation of similar biotherapeutic products (SBPs)*. The RBP should have been approved on the basis of a complete registration dossier, including safety and efficacy studies in each therapeutic indication. It should be fully identifiable (e.g. brand name, pharmaceutical form, formulation, strength, origin of the reference medicinal product, numbers and age of batches). The RBP should have been marketed for a suitable duration and should have a volume of marketed use in a jurisdiction that has a well-established regulatory framework and principles, as well as considerable experience of evaluation of biotherapeutic products and post-marketing surveillance activities.

In general, NRAs require the use of a nationally licensed RBP for the evaluation of the SBP. However, this practice may not be feasible for countries that lack nationally licensed RBPs. In case the RBP is not licensed in a given country, the NRA may set additional criteria for the selection of the RBP licensed or resourced in another country. The RBP should be licensed in another country with a complete dossier according to WHO's *Guidelines on the quality, safety and efficacy of biotherapeutic protein products prepared by recombinant DNA technology* or corresponding guidelines. The RBP should also have market experience that takes into account a significant duration and magnitude of exposure on the market. The manufacturer of the SBP should justify the use of an RBP that is not licensed locally and the same RBP should be used in all comparability studies of a given SBP.

### **QII-3 Under what circumstances would it be acceptable to use a foreign-sourced RBP?**

In general, the analytical and in vitro functional comparability of the SBP and the RBP should be demonstrated by using the locally-licensed and sourced product. The use of a foreign-sourced RBP may be feasible when the manufacturer plans a global development. By using this approach, unnecessary repetition of nonclinical and clinical studies can be avoided.

1 The use of a foreign-sourced RBP in nonclinical and clinical studies is possible if justified by  
2 information on the relationship of the manufacturers of locally-sourced and foreign-sourced  
3 RBP. For instance, the manufacturer may demonstrate that the locally-licensed RBP and the  
4 foreign-sourced RBP are versions of the same RBP, based on the same development data,  
5 including the same clinical data set. In some jurisdictions, comparability studies, such as  
6 analytical or even clinical pharmacokinetic (PK) data, are required to support the use of a  
7 foreign-sourced product.

8 In smaller jurisdictions, or in cases where there is no locally-licensed RBP, a foreign-sourced  
9 RBP may be used throughout the whole comparability exercise to demonstrate similarity to  
10 the SBP. The regulatory requirements in such a situation are described in the response to **QII-**  
11 **2.**

12

13 **QII-4 Can the SBP be approved when compared with an RBP which is not available**  
14 **on the domestic market?**

15 Yes, but it has to be justified. The manufacturers must take advice from the relevant NRA.

16

17 **QII-5 The guidelines state that “the same RBP should be used throughout the entire**  
18 **comparability exercise”. Can an RBP from another manufacturing site be used?**

19 Yes. Production batches from different manufacturing sites can be used provided that  
20 products from all manufacturing sites are approved by the relevant regulatory authority and  
21 that all RBP production batches used in the comparability exercise conform to the same  
22 specifications.

23

24

### **III. Quality:**

#### **QIII-1 Should the expression system used in producing an SBP be the same as the one used to produce the RBP?**

Not necessarily. The expression system (i.e. expression vector and production cells) need not be the same as for the RBP if the expressed protein has the same amino-acid sequence as well as a comparable higher-order structure and post-translational modifications. It is recommended that the manufacturers of SBPs use an expression system similar to that of the RBP where possible, since the cell type influences the pattern of post-translational modifications such as glycosylation. Differences between the RBP and SBP in the level and type of post-translational modifications need to be justified in terms of the potential to have an impact on the potency, safety and efficacy of the SBP.

The manufacturers of SBPs should also consider expression system-specific process impurities. In general, a manufacturer of an SBP is not able to use the same clone of production cells as the manufacturer of the RBP. The developers of an SBP must develop their own master cell banks for their production cells. If a company wishes to use a novel expression system this might give rise to different glycosylation patterns and new process-related impurities, and typically regulators would ask for more clinical immunogenicity data.

#### **QIII-2 Should the SBP have the same formulation as the RBP?**

Not necessarily, as long as the differences do not have an impact on the quality, safety and efficacy of the SBP, and the SBP and RBP can be demonstrated to be comparable. In addition, the manufacturer should justify potential differences between the formulations of the SBP and the RBP. In general, the formulations should be state-of-the-art with regard to stability, compatibility, integrity and impact on activity and strength of the active substance.

It is important to justify the lack of adverse impact on the relative efficacy and safety of the SBP if a different formulation and/or container/closure system is used – especially any material that is in contact with the medicinal product. The aim of the biosimilar comparability exercise is to demonstrate that the SBP and the RBP chosen by the manufacturer are comparable.

#### **QIII-3 Should the SBP have the same delivery device or container closure system as the RBP?**

No, it is not necessary for an SBP to have the same delivery device or container closure system as the RBP. The lack of any adverse impact of the delivery device/container closure system on quality, safety, efficacy and usability should be demonstrated. The manufacturer of an SBP should demonstrate that the product remains stable over long-term storage when stored in the chosen container closure systems.

1 Thus it is possible, for instance, to use a different delivery device, such as pre-filled syringe  
2 or autoinjector, even if the RBP has only a vial provided that the products are shown to be  
3 comparable.

4

5 **QIII-4 Should the SBP have the same strength as the RBP and how can this be**  
6 **demonstrated?**

7 Yes. In general, an SBP should have the same concentration of drug substance as the RBP.  
8 The total content of the drug substance per dosage form should be defined by the posology of  
9 the RBP and should allow the appropriate application. A difference in the total content of  
10 SBP and RBP should be justified. If needed, additional data should be provided. Any  
11 difference should not compromise safety. The total content and concentration should be  
12 expressed by using the same measurement system as the RBP (i.e. mass units or units of  
13 activity).

14

15 **QIII-5 Should the specifications of the SBP be the same as those of the RBP?**

16 The specifications control the most important RBP and SBP quality attributes concerning  
17 identity, purity, potency and molecular heterogeneity. Nevertheless, specifications of RBP  
18 and SBP are likely to be somewhat different because of different manufacturing processes  
19 and analytical methods. Thus, the specifications reflect the experience of the manufacturer's  
20 own product. The specifications should be based on WHO's *Guidelines on the quality, safety*  
21 *and efficacy of biotherapeutic protein products prepared by recombinant DNA technology*.

22 It should be noted that pharmacopoeial monographs provide only minimal requirements. It is  
23 expected that the specifications of an SBP do not allow significantly wider batch-to-batch  
24 variation than found for the RBP during the quality comparability exercise.

25

26 **QIII-6 How many batches must be analysed in the comprehensive comparability**  
27 **studies?**

28 The analysis of multiple batches of the RBP by the manufacturer is necessary for developing  
29 an optimal manufacturing process for a candidate SBP. For this purpose, the manufacturer of  
30 an SBP needs to collect a representative set of batches of the RBP over an extended period to  
31 justify comparability ranges for critical quality attributes. The relevance of the ranges should  
32 be discussed, taking into account the number of RBP batches tested, the quality attributes  
33 investigated, the age of the batches at the time of testing, and the evolution of quality  
34 attributes over time as well as the test method used. The age of the different batches of the  
35 RBP (relative to the expiry dates) should also be considered when establishing the target  
36 quality profile.

37 At the next stage, comprehensive head-to-head physico-chemical, structural and in vitro  
38 functional comparisons are performed for multiple representative batches of RBP and SBP to

1 confirm representative and comparable quality profiles. It may not be possible to set a  
2 definite number for batches of the comprehensive comparability exercise. The number of  
3 batches needed to show similarity of each quality attribute and to establish the range of SBP  
4 specifications should be sufficient to allow a meaningful comparison with the RBP. The  
5 manufacturers may request advice from the relevant regulatory authority on the appropriate  
6 number of batches when preliminary results from the degree of variability have been  
7 obtained.

8 Where several strengths or presentations are available, their selection should be appropriately  
9 justified.

10

#### 11 **QIII-7 What is the role of pharmacopoeial monographs in the evaluation of SBPs?**

12 Pharmacopoeial monographs are public standards which include quality requirements for  
13 medicinal products and their constituents. Monographs for biotherapeutic products have been  
14 issued in various jurisdictions. An SBP must show the same level of compliance with a  
15 pharmacopoeial monograph as the RBP. However, compliance with pharmacopoeial  
16 monographs will not be sufficient to demonstrate biosimilarity.

17

#### 18 **QIII-8 What is the role of reference standard materials in the evaluation of SBPs?**

19 WHO provides International Standards and Reference Reagents, which serve as primary  
20 reference standards of defined biological activity expressed in an international unit (IU) or  
21 unit (U).<sup>1</sup> They are used either to calibrate assays directly or to calibrate secondary standards  
22 (e.g. pharmacopoeial and national reference standards) or manufacturers' working standards.

23 When available, manufacturers can use international/pharmacopoeial reference standards and  
24 reagents for qualification and standardization of the tests used to characterize and quantify  
25 RBP and SBP. For example, the potency (expressed, for instance, in units or international  
26 units [IU]) is the quantitative measure of biological activity based on an attribute of the  
27 product. The potency of each batch of the drug substance and the final dosage form should be  
28 established by using, wherever possible, an appropriate national or international reference  
29 material which is normally calibrated in units of biological activity such as IU. In the absence  
30 of such preparations, an approved in-house reference preparation may be used for assay  
31 standardization.

32 Many biological products are labelled and dosed in terms of mass units rather than potency  
33 units. For such products, the reference standard (in-house, national or international) may be  
34 used to calibrate the working reference standard and the corresponding bioassay used to  
35 confirm product quality. In these situations, quality determination of bioactivity is normally  
36 expressed in percentage relative terms rather than in units and is not used for product  
37 labelling.

---

<sup>1</sup> See: [http://www.who.int/biologicals/reference\\_preparations/en/](http://www.who.int/biologicals/reference_preparations/en/) (accessed 19 July 2018).

1

2 However, these reference standards are distinct entities and cannot be used instead of the  
3 RBP for demonstration of comparability.

4

5 **QIII-9 How should the expiry date of an SBP be established?**

6 The expiry date of an SBP is based on the SBP stability data which defines its shelf-life and  
7 is independent of the RBP. The shelf-life of the SBP should be justified on the basis of full  
8 real-time and real-temperature stability data obtained according to the relevant guidelines,  
9 namely WHO's *Guidelines on the quality, safety and efficacy of biotherapeutic protein*  
10 *products prepared by recombinant DNA technology* and the ICH Q5C guideline on *Quality of*  
11 *biotechnological products: stability testing of biotechnological/biological products*.

12

13 **QIII-10 Are comparability studies in accelerated and stress stability tests needed?**

14 Stability testing of SBPs should comply with the relevant guidelines, namely: WHO's  
15 *Guidelines on the quality, safety and efficacy of biotherapeutic protein products prepared by*  
16 *recombinant DNA technology* and the ICH Q5C guideline on *Quality of biotechnological*  
17 *products: stability testing of biotechnological/biological products*. Stability studies on the  
18 drug product should be carried out in the intended drug product container closure system.

19 **Real-time/real-temperature stability tests** will determine the conditions for storage and the  
20 shelf-life of the SBP. These conditions may or may not be the same as those of the RBP.  
21 Comparative real-time, real-temperature stability studies between the SBP and RBP are not  
22 required.

23 **Comparative accelerated stability tests** not only provide important information on  
24 degradation pathways of the active substance and the suitability of the formulation and the  
25 container closure system but may also uncover differences between the degradation profiles  
26 of the SBP and RBP. Results obtained from the studies may show that additional controls  
27 should be used in the manufacturing process and during shipping and storage in order to  
28 ensure the integrity of the product.

29 **Stress stability testing** is necessary for an SBP in order to further investigate appropriate  
30 conditions for shipping and storage unless these conditions are covered by accelerated  
31 stability studies. In general, comparative stress testing of SBP and RBP does not provide  
32 added value. However, depending on the potential degradation mechanism of the molecule,  
33 stress conditions (e.g. high/low pH, humidity, oxidation) may reveal differences between the  
34 degradation profiles of the SBP and RBP.

35

36 **QIII-11 When conducting a comparability exercise, head-to-head characterization**  
37 **studies are required to compare the SBP and its RBP. How much difference or**



1           **what kinds of differences can be accepted while ensuring a high degree of**  
2           **similarity between the SBP and its RBP?**

3   The conclusion of high similarity is based on evaluation of the whole data package from  
4   quality, nonclinical and clinical parameters and not on an individual variable or physico-  
5   chemical test. The regulators may use their previous experience, generated for instance from  
6   changes introduced into manufacturing processes for the RBP, to understand the functional  
7   and clinical impact of a particular physico-chemical difference between the SBP and its RBP.

8   The results of physico-chemical tests should always be interpreted in the light of the  
9   performance of a particular analytical method and the batch-to-batch variability of the results.  
10   When available, orthogonal analytical techniques should always be used to strengthen the  
11   evaluation of comparability.

12   In vitro, usually cell-based, functional assays may be helpful in understanding the  
13   significance of a difference detected in the analytical testing. It is important to understand the  
14   factors that have an impact on the functional tests. The sensitivity of some of the functional  
15   tests, such as reporter gene-based assays, has been increased to the degree that they do not  
16   correspond to the physiological situation. In these situations, the manufacturer needs to  
17   consider the significance of the results and understand the difference between a robust assay  
18   for release and a bio-analytical assay. It is also important to consider other tests that may  
19   better reflect the physiological situation. Tests using cells from a specific patient population  
20   may also be helpful for interpretation of the observed difference.

21   In general, in vitro functional tests are more sensitive than clinical studies at detecting  
22   differences between the SBP and RBP. Results of physico-chemical and structural tests  
23   should be considered in planning the clinical comparability programme, especially in PK,  
24   pharmacodynamics (PD) and immunogenicity studies.

25   The PK of the SBP and RBP are often compared in single-dose studies involving healthy  
26   volunteers, when this is appropriate and depending on the nature of the treatment. The  
27   comparability range in the primary PK parameters should be defined and justified prior to  
28   conducting the study. The criteria used in the demonstration of bioequivalence of orally  
29   administered and chemically synthesized small molecules – i.e. 90% confidence interval (CI)  
30   of ratios of SBP to RBP – are often used for comparative PK studies of SBPs and RBPs in the  
31   absence of relevant historical data. If the PK comparability criteria are met but the exposure  
32   to SBP is significantly lower or higher, meaning that the CI of the SBP is entirely within  
33   either the higher or the lower side of the equivalence range, a root cause analysis and possibly  
34   new data could be needed. It is recommended that steady state PK should be measured in the  
35   repeat-dose safety and efficacy studies. This may mitigate concerns of some PK differences  
36   observed after a single-dose study.

37   The equivalence design is recommended for confirmatory efficacy and safety studies. Non-  
38   inferiority design may be used if superiority can be excluded. In both cases, the acceptance  
39   range is defined by previous clinical trials with the RBP and the difference is not clinically  
40   meaningful.

1 **QIII-12 How comprehensive should the evaluation of glycan structure (i.e. level of**  
2 **details) be?**

3 A glycoform is an isoform of a protein that differs from others only with respect to the  
4 number or type of attached glycans. The biotechnological manufacturing process of a given  
5 glycoprotein is sensitive to culture conditions, which may lead to production of different  
6 glycoforms in spite of the same glycosylation machinery. This glycoform pattern may to  
7 some extent vary from batch to batch. In addition, production cells from different species  
8 may produce qualitatively different glycans that should be identified and justified, especially  
9 if such glycan does not exist in humans.

10 For glycoproteins, carbohydrate structures should be thoroughly compared, including the  
11 overall glycan profile, site-specific glycosylation patterns and site occupancy. The extent of  
12 the comparative analysis of the glycoform patterns of the SBP and RBP depends on  
13 knowledge about the glycoform pattern of the RBP and the functional role of different  
14 glycoforms. Knowledge regarding the variation in the glycoform pattern between batches of  
15 the RBP will help in assessment of differences between the SBP and RBP.

16 Differences in the glycans and glycan profiles may have an impact on the structure, potency,  
17 PK, safety and efficacy of a product. For instance, sialylated, afucosylated and mannose-  
18 containing structures may display clinically significant variations.

19 Monoclonal antibodies are glycoproteins with glycosylation sites in the Fc portion of the  
20 heavy chains, with further possible glycosylation sites depending on the type of molecule.  
21 Monoclonal antibodies display several glycoforms that have different functional properties,  
22 such as differences in binding to Fc-receptors and complement. Therefore, a thorough  
23 analysis of the glycans attached to the Fc-protein backbone is necessary. These data, together  
24 with various binding and cell-based functional tests, will be crucial in the demonstration of  
25 comparability of an SBP and its RBP. Glycans are rarely immunogenic. However, glycans  
26 that are not normally present in humans may be immunogenic. For instance, alpha-gal-1, 3-  
27 gal that occurs on the carbohydrate moiety of proteins produced by some mammalian but not  
28 human cells may trigger serious hypersensitivity reactions in patients.

29

30 **QIII-13 How can statistical analysis support the demonstration of similarity of an SBP**  
31 **to the RBP in quality evaluation?**

32 Statistical methods have a crucial role to play in interpretation of comparative clinical data,  
33 especially PK and efficacy. The role of statistics in evaluation of biosimilarity is less clear  
34 with regard to the interpretation of results of comparative physico-chemical, structural and in  
35 vitro functional tests, and requires a different approach from that applied when analysing  
36 clinical data.

37 Statistical methods usually deal with means. The means may change within the acceptability  
38 range. Nevertheless, in some jurisdictions it has been suggested that statistical analyses of  
39 comparability data should be conducted in order to evaluate analytical similarity. Using a

1 descriptive statistical approach to establish ranges for quality attributes in the context of  
2 comparability is generally more widely accepted.

3 The establishment of similarity by statistical analysis may be influenced by the number of  
4 batches and observations, uncertainty regarding the clinical impact of an attribute and  
5 distribution of results, performance of the assays, source and age of the batch etc. In  
6 conclusion, the use of statistics in defining comparability is still at an empirical stage in most  
7 jurisdictions.

8 It is important to realize, however, that statistical tools, while helpful in supporting  
9 conclusions about similarity, should not be used as the sole basis for decision-making on  
10 biosimilarity for marketing authorization approval which should be based on evaluation of  
11 the whole data package for each of the quality, nonclinical and clinical parameters.

12

13

DRAFT

1 **IV. Nonclinical evaluation:**

2

3 **QIV-1 Which general factors should be considered for the planning/conduct of the**  
4 **nonclinical studies for an SBP?**

5 The nonclinical development of SBPs has evolved from merely abbreviated versions of the  
6 nonclinical development of original medicinal products to development programmes tailored  
7 to the specific features of SBP development.

8 Initially, significant emphasis was put on in vivo comparative nonclinical studies and the  
9 original WHO *Guidelines on evaluation of similar biotherapeutic products (SBPs)* required at  
10 least a head-to-head repeat-dose toxicity study. WHO's newer *Guidelines on evaluation of*  
11 *monoclonal antibodies as similar biotherapeutic products (SBPs)* promote a stepwise  
12 nonclinical development starting from demonstration of the physico-chemical and in vitro  
13 functional comparability before proceeding to the analysis of remaining uncertainties. If in  
14 vivo studies are considered to be indicated, the developer should clarify the availability of  
15 relevant animal models. If the drug substance of candidate SBP shows specific  
16 pharmacological activity only in great apes, the developer should seriously weigh the need for  
17 in vivo studies to avoid pharmaco-toxicological testing in these species. A consultation with  
18 the relevant NRA is recommended.

19

DRAFT

## 1 Nonclinical in vitro studies

2

### 3 **QIV-2 What kind of in vitro studies should be conducted for the nonclinical evaluation** 4 **of an SBP?**

5 The in vitro nonclinical studies should be comparative and should measure relevant  
6 biological activities of the drug substance. It is recommended that the tests are  
7 complementary or orthogonal in order to support the interpretation of results. Together, these  
8 assays should cover the whole spectrum of pharmacological aspects with potential clinical  
9 relevance for the RBP and for the product class. The manufacturer should discuss to what  
10 extent the in vitro assays used are representative/predictive of the clinical situation in terms of  
11 current scientific knowledge.

12 Typically, receptor-binding assays and cell-based functional assays are used to compare the  
13 functions of the SBP and RBP. The developer should justify the relevance, sensitivity and  
14 discriminatory capability of the tests by submitting qualification and or validation studies  
15 using the RBP and SBP. Test results should be given in units of activity calibrated against an  
16 international or national reference standard, where available.

17 For instance, monoclonal antibodies have several functionally active sites. Assays are  
18 available to measure the binding affinity and activity of the monoclonal antibodies as well as  
19 cell-based functional assays for each active site. The standard assays can be tailored to better  
20 reflect the physiological or pathological conditions in a particular therapeutic indication. A  
21 detailed analysis of the biological activity, including Fab- and/or Fc-mediated functions, such  
22 as ability to bind to different isoforms of Fc gamma and neonatal Fc receptors and to  
23 complement C1q, should be provided whether or not they are considered essential for the  
24 therapeutic mode of action. The absence of a mode of action should be considered by the  
25 SBP developer, although this may not require an extensive analytical demonstration and may  
26 be assessed via cell-based or binding assays. The corresponding cell-based functional assays,  
27 such as complement-dependent cytotoxicity (CDC), antibody-dependent cellular cytotoxicity  
28 (ADCC) and antibody-dependent cellular phagocytosis (ADCP) are important as they may  
29 play different roles in different therapeutic indications.

30 Where available, international reference standards can be used to support bioassay,  
31 characterization, calibration and performance. See also **QIII-8**.

32

### 33 **QIV-3 Which specific factors should be observed in the planning/conduct of the** 34 **nonclinical in vitro studies?**

35 It is important to understand what is known about the mechanism of action of the molecule  
36 for the selection of the relevant tests for the biological activity. The quality comparability  
37 studies may reveal differences that may have an impact on clinical performance, such as PK  
38 or efficacy. The nonclinical in vitro studies should be sensitive, specific and sufficiently  
39 discriminatory to show any potential differences which, according to current scientific  
40 knowledge, could be of potential clinical relevance. Some assays used in the quality

1 assessment may be utilized to inform nonclinical studies. In these cases, the clinical relevance  
2 of these assays should be justified. Since in vitro assays may often be more specific and  
3 sensitive for detecting differences between SBP and RBP than studies in animals, such assays  
4 can be considered paramount for the nonclinical biosimilar comparability exercise.

5

6

7

DRAFT

## Nonclinical in vivo studies

### **QIV-4 Which factors should be considered when deciding whether in vivo animal studies are required for nonclinical evaluation of a specific SBP?**

On the basis of the totality of available quality and nonclinical in vitro data and the extent of residual uncertainty about the similarity of SBP and RBP, nonclinical in vivo studies may not be required. If the quality-comparability exercise and nonclinical in vitro studies are considered satisfactory and no issues that would prevent direct entrance into humans are identified, in vivo animal studies may be considered unnecessary.

In some jurisdictions, legislation requires the application of the 3R (Reduction, Refinement and Replacement of animal experiments) principle in product development in order to reduce the suffering of animals. In particular, studies with non-human primates should be avoided if possible. In vivo animal studies should be considered only when it is expected that such studies would provide relevant additional information. In general, the additional value of in vivo nonclinical studies for the demonstration of comparability of SBP and RBP is questionable when previous physico-chemical, structural and in vitro functional tests have demonstrated the similarity of the SBP and RBP.

A number of factors reduce the need for in vivo studies in the development of an SBP:

- The risk of first-in-man use of an SBP can usually be estimated on the basis of knowledge about the clinical safety profile of the RBP and the outcome of the physico-chemical, structural and in vitro functional tests with the SBP.
- Most toxic effects of therapeutic proteins are related to an exaggeration of their known pharmacological effects.
- The functional activity of a biotherapeutic drug substance is often species-specific, making it difficult to identify a suitable animal species.
- Human drug substances are often immunogenic in conventional animal models due to species-specificity, which prevents or hampers the interpretation of repeat-dose animal studies
- Conventional animal models are often not sensitive enough to detect small differences.

### **QIV-5 Which specific factors should be considered in the planning/conduct of in vivo animal studies on pharmacodynamics and/or pharmacokinetics of an SBP?**

PK studies with the SBP should be justified on the basis of RBP data and the interference of anti-drug antibodies.

If product-inherent factors that have an impact on PK and/or biodistribution (such as glycosylation or pegylation) cannot be characterized sufficiently at a quality and in vitro level, the manufacturer should carefully consider if in vivo animal PK and/or PD studies should be performed in advance of clinical PK/PD testing. Since relevant PK/PD data are

1 obtained in humans, nonclinical PK/PD studies usually have little added value for the  
2 comparability exercise.

3 WHO's guidelines indicate that, if an in vivo PK/PD study is conducted, the PK and/or PD of the  
4 SBP and the RBP should be compared quantitatively, including, if feasible, a dose-response  
5 assessment that includes the intended exposure in humans.

6 In vivo assays, if warranted (see **QIV-4**), may include the use of animal models of disease to  
7 evaluate functional effects on PD markers or efficacy measures. PK measurements may need  
8 to be performed in parallel in order to interpret the study results.

9

10 **QIV-6 Which specific factors should be considered in the planning/conduct of in vivo**  
11 **animal toxicity studies for an SBP?**

12 Most toxic effects of therapeutic proteins are related to their pharmacological mechanism of  
13 action which can be characterized by receptor-binding assays and in vitro nonclinical  
14 functional tests, including cell-based assays. Therefore, with regard to the conduct of  
15 toxicological studies, the developer should focus on other types of adverse effects known to  
16 occur following treatment with the RBP and adverse effects that could potentially be caused  
17 by the differences observed during the preceding steps of the comparability exercise.

18 If a toxicity study is considered, the suitability of conventional toxicology models needs to be  
19 evaluated. In vivo toxicological studies should be conducted only in an animal species in  
20 which the SBP is pharmacologically active. However, many biological products may not be  
21 pharmacologically/toxicologically active in the species used in conventional toxicology tests.  
22 In addition, human proteins are often immunogenic in other species, thus restricting the  
23 duration of toxicology studies and hampering the interpretation of study results. Also, the  
24 discriminatory ability of the in vivo model in a reasonably-sized study, especially in multiple  
25 dose studies, should be evaluated realistically.

26 If in vivo safety studies are deemed necessary, a flexible approach should be considered (e.g.  
27 in accordance with the 3R principles). The conduct of repeat-dose toxicity studies in non-  
28 human primates is usually not recommended (see **QIV-1**). If appropriately justified, a study  
29 with refined design (such as use of just one dose level of SBP and RBP and/or just one sex  
30 and/or no recovery animals) and/or an in-life evaluation of safety parameters (such as clinical  
31 signs, body weight and vital functions) may be considered. Depending on the selected end-  
32 points, it may not be necessary to euthanize the animals at the end of the study.

33 Local tolerance may be evaluated in the context of a repeat-dose toxicity study, if one is  
34 performed. Safety pharmacology, reproductive toxicology, genotoxicity and carcinogenicity  
35 studies are not needed.

36

37



1 **QIV-7 Where no suitable animal model is available, how can the nonclinical**  
2 **comparability exercise be extended?**

3 First, the developer needs to consider whether in vivo nonclinical studies are necessary (see  
4 **QIV-4**). If the risk analysis based on data from the physico-chemical, structural and in vitro  
5 functional comparability studies raises concerns about the transition to clinical studies, the  
6 developer may consider the following options:

- 7 • optimization of the manufacturing process to remove factors that raise concerns  
8 (e.g. reduction of impurities or modification of the formulation);
- 9 • performance of additional tailored quality or nonclinical studies designed to reduce  
10 residual uncertainty;
- 11 • application of specific risk mitigation measures upon entry to clinical studies.

12

13 **QIV-8 Under what circumstances/conditions would additional in vivo nonclinical**  
14 **comparability studies be required?**

15 In vivo nonclinical studies should be considered if there is one or more of the following:

- 16 • a significant functional difference suggested by nonclinical in vitro studies;
- 17 • a novel excipient in the formulation of the SBP which may justify a more thorough  
18 nonclinical programme to assure the safety of the excipient in its intended route of  
19 administration;
- 20 • a new expression system or purification process in the manufacturing process, leading  
21 to a significant change in the process-related impurities;
- 22 • a narrow therapeutic window for the drug substance.

23 Although these factors may not necessarily always warrant in vivo testing, the factors should  
24 be considered when assessing the level of concern and when determining whether there is a  
25 need for in vivo testing.

## 1 **V. Clinical evaluation:**

2

### 3 **QV-1 What is the role of clinical evaluation in SBP development?**

4 The purpose of the clinical comparability programme for an SBP is to confirm similarity to  
5 the RBP rather than independently to establish its own efficacy and safety profile. An SBP  
6 relies on safety/efficacy data and knowledge gained from the RBP. The SBP clinical study  
7 programme should be designed with the use of sensitive models (e.g. disease  
8 indications/populations) to detect clinically meaningful differences. Clinical trials aim to  
9 resolve uncertainties regarding the similarity of the candidate SBP with the RBP.

10

### 11 **QV-2 What is immunogenicity and which factors should be considered in terms of** 12 **immunogenicity for an SBP?**

13 The purpose of the immune system is to recognize and eliminate foreign substances and  
14 denatured structures of the body itself. Immunogenicity of a therapeutic protein means that  
15 the immune system is capable of recognizing the protein as non-self and is able to generate an  
16 immune response against it. Unfortunately, this immune response can sometimes recognize  
17 therapeutic proteins as foreign invaders and react against them. This reaction may abolish the  
18 therapeutic effect and cause hypersensitivity and autoimmune reactions.

19 The human immune system has evolved to recognize proteins, including therapeutic proteins.  
20 If a protein is deemed foreign, non-self, the immune system will mount an immune response  
21 against the protein. If the protein is classified as a normal body constituent – i.e. “self” – no  
22 reaction is triggered. Thus, there is an immunological tolerance to the protein. The  
23 immunological tolerance varies between individuals as it is partly genetically determined.

24 An immune response to a therapeutic protein is usually detected by measuring anti-drug  
25 antibodies (ADAs). An ADA response may be transient and may not have any clinical  
26 consequences. However, ADAs may neutralize the effect of a biotherapeutic product and lead  
27 to a loss of efficacy. Safety problems may arise if the ADA-response continues to evolve by  
28 immunoglobulin class switch, antibody affinity maturation and epitope-spreading. Life-  
29 threatening hypersensitive reactions may occur if the ADAs undergo a class switch to IgE or  
30 if pathogenic immune complexes (therapeutic protein + ADA) are formed. Another type of  
31 a serious reaction is possible if the therapeutic protein has an endogenous counterpart. In this  
32 situation, ADAs may cross-react with the endogenous protein and cause serious  
33 complications, as noted in the case of anti-erythropoietin antibodies which cause pure red cell  
34 aplasia.

35 According to WHO guidelines, all new therapeutic proteins, including SBPs and RBPs,  
36 should be tested for ADAs in clinical trials. The additional challenge for SBPs is the need to  
37 demonstrate comparable immunogenicity to the RBP. This is done first at the quality level by  
38 demonstrating that the amino acid sequence, and therefore the backbone epitopes, is identical  
39 between SBP and RBP. In addition, potential immunogenic impurities (e.g. aggregates, non-

1 human glycans, host-cell proteins) need to be controlled at sufficiently low amounts. For final  
2 confirmation, an SBP is always compared head-to-head to its RBP in pre-marketing clinical  
3 trials to demonstrate comparable PK, immunogenicity, efficacy and immune-mediated  
4 adverse effects. The scope and extent of comparative immunogenicity evaluations should  
5 take into account prior knowledge concerning immunogenicity of the RBP, the route of  
6 administration, and product- and patient-specific factors. An SBP cannot have more immune-  
7 mediated adverse effects than its RBP. An RBP may have several therapeutic indications but  
8 an SBP is tested usually only on one of them. Therefore, it is important to study a therapeutic  
9 indication and patient population that provides a sensitive model for detecting differences in  
10 immunogenicity. To date, no SBP has caused more adverse immune reactions than its RBP,  
11 so long as it was developed according to WHO and other corresponding guidelines and  
12 assessed by regulatory agencies with the necessary scientific expertise and experience.

13

#### 14 **QV-3 What duration of immunogenicity is required in the clinical studies?**

15 The immune response to a biotherapeutic product evolves over time. Immunogenicity studies  
16 aim to characterize the immune response for the incidence, titre, neutralizing activity and  
17 persistence of ADAs. Sampling for ADAs in the comparative clinical PD, efficacy and safety  
18 studies is important for investigating the relative clinical impact of a potential immune  
19 response.

20 The duration on pre-licensing immunogenicity studies depends on the duration of treatment  
21 and the nature of the observed immune response and should be justified. In chronic treatment,  
22 the minimum follow-up of immunogenicity is 6 months. A longer follow-up is often  
23 necessary to determine the persistence and clinical impact of the immune response. This is  
24 also important for biosimilars in order to demonstrate a comparable evolution of the immune  
25 responses to SBP and RBP.

26

#### 27 **QV-4 How are differences in immunogenicity handled?**

28 The purpose of immunological studies is to detect harmful immunogenicity in the clinically  
29 relevant population. The first step is to compare the incidence, titre, persistence over time and  
30 neutralizing capacity of the induced ADAs. Secondly, the possible clinical correlations  
31 should be investigated. Differences in efficacy and safety arising from differences in  
32 immunogenicity are not tolerated.

33 The ADA assays should preferably be capable of detecting antibodies against both the  
34 biosimilar and the reference molecule but should at least be able to detect all antibodies  
35 developed against the biosimilar molecule.

36 The root cause of a difference in immunogenicity should always be investigated, even if the  
37 SBP appears to be less immunogenic. First of all, the ADA assay should be re-evaluated for  
38 possible bias. The most common problem in the ADA assays is drug interference in which  
39 the residual product in the blood sample for ADA analysis causes false negative results.

1 Therefore, the drug tolerance of the assay(s) should be revisited and the drug concentrations  
2 in the samples compared.

3 If no technical problem is discovered, the manufacturer should review all differences  
4 observed in the analytical, structural and functional comparisons and discuss their possible  
5 role in immunogenicity.

6 If differences in ADA incidences or titres, including neutralizing ADAs, are observed, the  
7 persistence of the ADA responses and possible clinical correlations should be explored by  
8 comparing PK, recording relevant symptom complexes such as hypersensitivity or  
9 autoimmunity, and comparing cumulative drug doses of the SBP and RBP in relevant clinical  
10 studies.

11 If the SBP is indeed less immunogenic on the basis of ADA-assays, the manufacturer should  
12 ensure that there is no impact on exposure. If exposure is increased as a result of reduced  
13 immunogenicity, the manufacturer should discuss the safety implications of the increased  
14 exposure.

15 The burden of evidence is on the manufacturer of the SBP who must convince regulators of  
16 the lack of clinical impact of a difference in immunogenicity. If no harmful effects are  
17 observed, the manufacturer may have to commit to post-marketing studies to exclude  
18 potential rare immunological complications of the SBP and to ensure a positive benefit–risk  
19 balance.

20

21 **QV-5 If the RBP shows a higher rate of anti-drug antibodies than the historical data,  
22 what would be the data requirement for the SBP?**

23 It is not uncommon for the incidence of ADAs to be lower in older studies of the RBPs than  
24 in newer ones. This can be explained by the higher sensitivity of current ADA assays. For  
25 this reason, head-to-head comparisons using validated state-of-the-art assays are the only way  
26 to demonstrate comparable immunogenicity. Deviations from this rule may be allowable in  
27 low-risk situations after consultation with local competent authorities on a case-by-case basis.

28

29 **QV-6 If the comparability study of efficacy is waived, is a separate immunogenicity  
30 study required or could immunogenicity assessment be conducted in a  
31 comparative PK/PD study?**

32 Immunogenicity studies should be integrated in the clinical comparability studies because the  
33 purpose is to detect harmful immunogenicity. In principle, the analysis of immunogenicity  
34 should be conducted in a population in which differences can be detected and in a study that  
35 allows the investigation of the possible clinical impact of ADAs.

36 ADAs should be investigated in PK studies because of the potential interference they cause.  
37 PD studies in the target population are suitable for investigation of immunogenicity if a  
38 surrogate PD marker is used.

1 If other kinds of PD studies are conducted, additional specific immunogenicity studies may  
2 be needed pre- or post-marketing unless the product is expected to have a low risk of  
3 immunogenicity. A consultation with the local regulatory authorities is warranted (see **QV-**  
4 **12**).

5

6 **QV-7 How can SBPs be approved for indications for which no clinical studies have**  
7 **been conducted?**

8 The aim of the biosimilar comparability studies is to demonstrate a high similarity between  
9 the SBP and RBP. If this is achieved, it can be expected that the function of the products is  
10 also similar. Additional studies are needed if the therapeutic indication that was investigated  
11 in the clinical comparability study is not representative of other requested therapeutic  
12 indications in terms of safety and efficacy (see **QV-8**).

13

14 **QV-8 What are the most important “points to consider” in extrapolating clinical data**  
15 **showing biosimilarity in one indication to other licensed indications of the RBP?**

16 Clinical studies of an SBP are part of the overall comparability exercise. The ability to  
17 extrapolate is based on the totality of evidence (see **QI-2**). If a close similarity has been  
18 demonstrated, extrapolation is possible. Nevertheless, as described in WHO’s *Guidelines on*  
19 *evaluation of similar biotherapeutic products (SBPs)* and *Guidelines on evaluation of*  
20 *monoclonal antibodies as similar biotherapeutic products (SBPs)*, a scientific justification  
21 should be presented with consideration of the following points:

22 • **What is the sensitivity of the studied clinical model (therapeutic indication and**  
23 **patient population) in detecting differences?**

24 This means that the therapeutic effect should be significant and consistent across the  
25 clinical trials and that there are sensitive clinical endpoints for comparing the  
26 outcomes.

27 • **Are the same receptors or binding sites involved in the effects of the drug**  
28 **substance in all therapeutic indications claimed for the SBP?**

29 Extrapolation may be straightforward if the same receptors or active sites are involved  
30 in the therapeutic indications (e.g. epoetin alfa).

31 For monoclonal antibodies, extrapolation is more complicated since there are several  
32 receptors/functional sites that can mediate or modify therapeutic effects and the  
33 relative importance of individual receptors/active sites may vary between the  
34 approved therapeutic indications of the RBP. Therefore, the binding and function of  
35 the relevant receptors/functional sites should be examined. In some cases, functional  
36 tests need to be modified by using different target and effector cells to better simulate  
37 the pathology of the target disease. Additional PD or clinical efficacy and safety  
38 studies may be considered although they may not be as sensitive as in vitro functional  
39 tests.

- 1       • **Are there specific concerns in the therapeutic indications that were not**  
2       **investigated or cannot be addressed by data obtained from the clinical trial(s)?**  
3       Immunogenicity may vary between therapeutic indications as a result of differences in  
4       the state of the immune system. Another concern is extrapolation from one disease  
5       group to another (e.g. from autoimmune disease to cancer) where the PK and  
6       posology may be different. In these cases, additional PK/PD or clinical trials may be  
7       needed to address the residual uncertainty. Potential rare adverse effects should also  
8       be monitored post-marketing.

9  
10   **QV-9   After an SBP has been approved, can a new indication added to the RBP be**  
11   **shared with the SBP?**

12   In principle, a new therapeutic indication added to the RBP may be shared with the SBP.  
13   However, an appropriate scientific justification should be provided along the same principles  
14   as extrapolation before approval of the SBP.

15  
16   **QV-10   Why are different regulatory decisions on extrapolation reached by different**  
17   **national regulatory authorities when using the same regulatory data package?**

18   There may be some differences in the marketing authorization conditions granted by different  
19   regulatory authorities. In addition, it is not usually known whether the same data to support  
20   extrapolation was submitted to different authorities, especially when the submissions took  
21   place at different times. The regulatory history of the RBP, including manufacturing changes  
22   and labelled therapeutic indication as well as local guidelines and regulatory policies, may  
23   also vary in different jurisdictions. Moreover, some regulatory bodies may have a lot of  
24   experience with extrapolation whereas some regulators have only recently been exposed to it.  
25   In some areas, SBPs, including extrapolation, have been controversial among stakeholders.  
26   Additionally, the estimation of benefit–risk balance involves values and uncertainties that  
27   may be judged differently.

28   However, differences in the initial regulatory decisions on extrapolation are expected to  
29   diminish over time as when more post-marketing safety data and new clinical data become  
30   available. For instance, there were initially differences between regulatory bodies concerning  
31   the extrapolation of efficacy and safety of the first infliximab SBP from rheumatic diseases to  
32   inflammatory bowel diseases. Nevertheless, within a few years all major regulatory bodies  
33   reached the same conclusion on the basis of increased experience.

34  
35   **QV-11   How should inexperienced NRAs deal with differing regulatory decisions of**  
36   **major experienced NRAs?**

37   In general, the major experienced regulatory bodies have reached similar conclusions and  
38   decisions on SBPs. However, national legislations may introduce some differences in the  
39   regulatory approach. For instance, legislation in the USA provides additional approval

1 criteria for interchangeable SBPs whereas European legislation prohibits the European  
2 Medicines Agency from taking a position on interchangeability. The same is true in Canada  
3 where interchangeability decisions are in the hands of the provincial health authorities.  
4 Consequently, it is important to understand the background to regulatory decisions.

5  
6 Differences in judgement/interpretation of scientific data exist across regulatory agencies (see  
7 **QV-10**). In such cases, in order to understand the reasons for the different interpretations, it is  
8 helpful to read publicly available assessment reports of regulatory agencies that have reached  
9 different conclusions. In addition, it may be useful to review post-marketing data on safety  
10 and efficacy from the NRA that made the positive decision.

### 11 12 **QV-12 Is there always a need to conduct a clinical study for an SBP?**

13 As noted in WHO's *Guidelines on evaluation of similar biotherapeutic products (SBPs)*, the  
14 demonstration of comparability of an SBP to its RBP in terms of quality is a prerequisite for  
15 the reduction of the nonclinical and clinical data set required for licensure. Thus, the WHO  
16 guidelines mention the reduction but not the complete omission of clinical data.

17 The complexity of biotherapeutic products varies enormously from simple linear peptides to  
18 large macromolecules with secondary, tertiary and quaternary structures and extensive post-  
19 translational modifications. The analytical methodology has developed rapidly during the era  
20 of SBPs. As a result, even complex biotechnology-derived products such as monoclonal  
21 antibodies can be characterized to a degree that may allow an abbreviated clinical  
22 development (see WHO's *Guidelines on evaluation of monoclonal antibodies as similar*  
23 *biotherapeutic products (SBPs)*).

24 For less complex proteins or polypeptides such as insulin and filgrastim (G-CSF),  
25 confirmatory PK/PD studies may be appropriate, provided that a PD marker can be regarded  
26 as a surrogate for efficacy. Thus, the euglycaemic clamp test is a suitable surrogate PD  
27 marker for the efficacy of insulin SBPs and absolute neutrophil count (duration of severe  
28 neutropenia) has been used in confirmatory studies of filgrastim SBPs. However, regulatory  
29 authorities may require additional safety studies in the target population.

30 Very simple peptides may be licensed with only a small PK/PD bioequivalence study. For  
31 instance, teriparatide is a 34 amino acid peptide that can be synthesized both chemically and  
32 by biotechnology. The peptide undergoes no post-translational modification. Synthetic and  
33 genetically engineered versions of teriparatide have identical affinity for the parathyroid  
34 hormone (PTH) surface receptors as well as the same biological activity. Thus, it is logical  
35 that regulatory authorities have required only a simple bioequivalence study with supportive  
36 PD markers.

37 In conclusion, some pre-licensing clinical data are always required for an SBP but the clinical  
38 development can be abbreviated, as outlined by the WHO guidelines for SBPs.

1 **VI. Pharmacovigilance:**

2

3 **QVI-1 Will SBPs be as safe as originator products?**

4 Yes, if they are developed according to WHO's and other corresponding guidelines and  
5 assessed by regulatory agencies that have the necessary scientific expertise and experience.  
6 For example, it is estimated that approximately 700 000 000 doses of SBPs authorized in the  
7 EU had been administered by 2016. In spite of the large exposure, no SBPs have been  
8 withdrawn for safety reasons and no new adverse effects have been reported that have not  
9 been reported for the reference products as well. The equal safety of the SBP and its RBP is  
10 based on the physico-chemical and structural similarity that is demonstrated by the extensive  
11 comparability exercise comprising analytical, structural and functional tests, as well as  
12 clinical data. Depending on the nature of the SBP, more or less extensive clinical testing with  
13 efficacy and safety data may be necessary in addition to PK data. The safety of SBPs is  
14 monitored by pharmacovigilance systems and often by additional post-marketing risk  
15 detection and minimization measures.

16

17 **QVI-2 After an SBP has been approved, is the SBP required to show the maintenance**  
18 **of biosimilarity with its RBP?**

19 No. Following approval, many NRAs consider that an SBP has its own life cycle and there is  
20 no formal requirement to re-establish similarity to the reference product when comparability  
21 exercises are conducted upon manufacturing changes (see WHO's *Guidelines on procedures*  
22 *and data requirements changes to approved biotherapeutic products*). Every significant  
23 change in the manufacturing process of biotherapeutic products must be supported by a  
24 comparability exercise comparing the pre- and post-change versions of the product to  
25 demonstrate that the safety and efficacy have not been altered.

26 The manufacturers of both SBP and RBP are responsible for ensuring that their products  
27 remain safe and efficacious throughout their life cycle by preventing significant changes to  
28 the product. Experience from hundreds of manufacturing changes introduced for RBPs over  
29 several decades demonstrates that significant changes to individual products over time are  
30 very rare. At this point in time, there are no data to suggest that an SBP lost its similarity to  
31 the RBP following manufacturing changes. However, when new safety information is added  
32 in the product information of the RBP after the original approval of the SBP, labelling  
33 information of the SBP should follow the changes made in the RBP unless it can be  
34 demonstrated that the new information on the RBP is not relevant to the SBP. In that context,  
35 it is important to emphasize that these data could be obtained only by having robust  
36 pharmacovigilance systems in place, including unique product identification that allows the  
37 collection of product-specific data.

38



1 **QVI-3 Would it be beneficial to review/discuss post-marketing commitments from**  
2 **each NRA after extrapolation of indications?**

3 Yes. It is always appropriate to discuss post-marketing commitments prior to initial approval.  
4 NRAs may ask for specific risk detection measures to address possible safety concerns in the  
5 “extrapolated therapeutic indications” after licensure. Risk detection measures may range  
6 from the monitoring of specific adverse events to patient registries and specific clinical trials.  
7 Risk minimization measures may include strengthening of product labelling to highlight new  
8 safety information or the provision of educational materials for health-care providers and/or  
9 patients. These measures are determined by each NRA and may differ across different  
10 jurisdictions. Where possible, it would be beneficial to harmonize the post-marketing  
11 commitments of NRAs to allow for pooling data to facilitate safety signal detection.

12  
13 **QVI-4 If safety information on the RBP (i.e. as the result of adverse events) is**  
14 **amended, how would it be applied to SBPs that are already approved?**

15 This is a national regulatory decision. In principle, new safety information should be added to  
16 SBP in view of the fact that the approval of an SBP is based on comparable safety and  
17 efficacy of SBP and RBP. The manufacturer of the SBP should submit a variation to update  
18 its safety information to the relevant regulatory agencies unless it can be demonstrated that  
19 the new information on the RBP is not relevant to the SBP.

20  
21 **QVI-5 Can the SBP marketing authorization holder seek approval for a new**  
22 **indication, dosage form or route of administration that is different from the**  
23 **RBP?**

24 In principle yes, if the marketing authorization holder submits relevant data to support the  
25 application. The requirements may follow the data requirements applicable to a stand-alone  
26 application – such as the efficacy, safety and immunogenicity profile of the SBP in the new  
27 indication or at the new dosage and route of administration that have not previously been  
28 established. This depends, however, on the regulations of the specific NRA. The  
29 manufacturer of the SBP should consult the local NRA when planning studies for the new  
30 indication, dosage form or route of administration.

31  
32 **QVI-6 Should cautions for the use of an SBP be the same as those for the licensed RBP?**

33 Yes. In general, the product information (PI) of the SBP should be in line with the PI of the  
34 RBP except for product-specific differences. For reasons of public health (e.g. possible off-  
35 label use), cautions for use of all therapeutic indications for the RBP should be included in  
36 the PI of the SBP even when the cautions are related to a therapeutic indication that was not  
37 applied for.

38

39

## 1 Authors and acknowledgements

2

3 The **first draft** document was prepared by Dr H-N. Kang, World Health Organization,  
4 Geneva, Switzerland and Dr P. Kurki, University of Helsinki, Helsinki, Finland taking into  
5 consideration comments from Dr K. Gao, China Food and Drug Administration, Beijing,  
6 China; Dr E. Griffiths, Consultant, Kingston upon Thames, United Kingdom; Dr H-K. Heim,  
7 Federal Institute for Drugs and Medical Devices, Bonn, Germany; Dr S. Suh, Ministry of  
8 Food and Drug Safety, Chungcheongbuk-do, Republic of Korea; and Dr M. Wadhwa,  
9 National Institute for Biological Standards and Control, Potters Bar, United Kingdom.

10

11 The draft document was then posted on the WHO Biologicals website for the first round of  
12 public consultation from 12 December 2017 to 23 February 2018 and comments were  
13 received from the following reviewers: T. Bell (*provided the consolidated comments of the*  
14 *Center for Drug Research and Evaluation of U.S. Food and Drug Administration*), USA; Mrs  
15 J. Bernat (*provided the consolidated comments of the International Federation of*  
16 *Pharmaceutical Manufacturers & Associations*), Switzerland; Dr E. Charton, European  
17 Directorate for the Quality of Medicines & HealthCare, France; Ms M. Delgado Just  
18 (*provided the consolidated comments of the Biosimilar Medicinal Products Working Party of*  
19 *the European Medicines Agency*), United Kingdom; L. Feisee (*provided the consolidated*  
20 *comments of the Biotechnology Innovation Organization*), USA; Dr E. Griffiths (*provided the*  
21 *consolidated comments of Health Canada*), Canada; Dr H-K. Heim, Federal Institute for  
22 Drugs and Medical Devices, Germany; Ms E. Hernandez (*provided the consolidated*  
23 *comments of the Vaccine Prequalification Team, WHO*), Switzerland; Dr Y. Khoo, National  
24 Pharmaceutical Regulatory Agency, Malaysia; Dr Y. Kishioka, Pharmaceuticals and Medical  
25 Devices Agency, Japan; Mrs S. Kox (*provided the consolidated comments of the Biosimilars*  
26 *Committee of the International Generic and Biosimilar Medicines Association (IGBA)*),  
27 Belgium; Dr Z. Kusynova (*provided the consolidated comments of the International*  
28 *Pharmaceutical Federation*), Netherlands; Dr D. Lottaz, Swissmedic, Switzerland; Dr B.  
29 Nhaquila, Ministry of Health, Mozambique; Dr I. Oh, Ministry of Food and Drug Safety,  
30 Republic of Korea; Dr T-J. Seng (*provided the consolidated comments of the Health Sciences*  
31 *Authority*), Singapore; Dr J. Southern, Consultant, South Africa; Dr M. Wadhwa, National  
32 Institute for Biological Standards and Control, United Kingdom.

33

34 The document **WHO/BS/2018.2352** was prepared by Dr H-N. Kang, World Health  
35 Organization, Geneva, Switzerland and Dr P. Kurki, University of Helsinki, Helsinki, Finland  
36 taking into consideration comments from Dr K. Gao, China Food and Drug Administration,  
37 Beijing, China; Dr E. Griffiths, Consultant, Kingston upon Thames, United Kingdom; Dr H-  
38 K. Heim, Federal Institute for Drugs and Medical Devices, Bonn, Germany; Dr I. Oh,  
39 Ministry of Food and Drug Safety, Chungcheongbuk-do, Republic of Korea; and Dr M.  
40 Wadhwa, National Institute for Biological Standards and Control, Potters Bar, United  
41 Kingdom, taking into consideration comments received from the first round of public  
42 consultation.

43

44 The document **WHO/BS/2018.2352** is now being posted on the WHO Biologicals website  
45 for a second round of public consultation from xx July to 20 September 2018.

## Other recommended reading

1. Guidelines on evaluation of similar biotherapeutic products (SBPs). In: WHO Expert Committee on Biological Standardization: sixtieth report. Geneva: World Health Organization; 2013: Annex 2 (WHO Technical Report Series, No. 977; [http://www.who.int/biologicals/expert\\_committee/TRS\\_977\\_60th\\_report.pdf?ua=1](http://www.who.int/biologicals/expert_committee/TRS_977_60th_report.pdf?ua=1), accessed 19 July 2018).
2. Regulatory assessment of approved rDNA-derived biotherapeutics. In: WHO Expert Committee on Biological Standardization: sixty-sixth report. Geneva: World Health Organization; 2016: Annex 3 (WHO Technical Report Series, No. 999; [http://www.who.int/biologicals/areas/biological\\_therapeutics/Annex\\_3\\_Regulatory\\_assessment\\_of\\_approved\\_rDNA-derived\\_biotherapeutics.pdf?ua=1](http://www.who.int/biologicals/areas/biological_therapeutics/Annex_3_Regulatory_assessment_of_approved_rDNA-derived_biotherapeutics.pdf?ua=1), accessed 19 July 2018).
3. Resolution WHA67.21. Access to biotherapeutic products including similar biotherapeutics products and ensuring their quality, safety and efficacy. Sixty-seventh World Health Assembly, Geneva, 18–26 May 2014. Geneva: World Health Organization; 2014 ([http://apps.who.int/gb/ebwha/pdf\\_files/WHA67/A67\\_R21-en.pdf](http://apps.who.int/gb/ebwha/pdf_files/WHA67/A67_R21-en.pdf), accessed 19 July 2018).
4. Guidelines on evaluation of monoclonal antibodies as similar biotherapeutic products (SBPs). In: WHO Expert Committee on Biological Standardization: sixty-seventh report. Geneva: World Health Organization; 2017: Annex 2 (WHO Technical Report Series, No. 1004; [http://who.int/biologicals/biotherapeutics/WHO\\_TRS\\_1004\\_web\\_Annex\\_2.pdf?ua=1](http://who.int/biologicals/biotherapeutics/WHO_TRS_1004_web_Annex_2.pdf?ua=1), accessed 19 July 2018).
5. Guidelines on procedures and data requirements for changes to approved biotherapeutic products. Adopted by the sixty-eighth WHO Expert Committee on Biological Standardization; 2017 ([http://who.int/biologicals/expert\\_committee/PAC\\_highlighted\\_20\\_Oct\\_2017.HK.IK.pdf?ua=1](http://who.int/biologicals/expert_committee/PAC_highlighted_20_Oct_2017.HK.IK.pdf?ua=1), accessed 19 July 2018).
6. Guidelines on the quality, safety and efficacy of biotherapeutic protein products prepared by recombinant DNA technology. In: WHO Expert Committee on Biological Standardization: sixty-fourth report. Geneva: World Health Organization; 2014: Annex 4 (WHO Technical Report Series, No. 987; [http://who.int/biologicals/biotherapeutics/TRS\\_987\\_Annex4.pdf?ua=1](http://who.int/biologicals/biotherapeutics/TRS_987_Annex4.pdf?ua=1), accessed 19 July 2018).
7. Quality of biotechnological products. Stability testing of biotechnological/biological products. ICH Guideline Q5C. Geneva: International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use; 1995.
8. Abbreviated licensing pathways for biological therapeutic products. In: WHO Expert Committee on Biological Standardization: fifty-ninth report. Geneva: World Health Organization; 2012 (WHO Technical Report Series, No. 964:14–15; [http://www.who.int/biologicals/WHO\\_TRS\\_964\\_web.pdf?ua=1](http://www.who.int/biologicals/WHO_TRS_964_web.pdf?ua=1), accessed 19 July 2018).
9. Vaccines and biotherapeutics: recent and planned activities in biological standardization. In: WHO Expert Committee on Biological Standardization: sixty-sixth

- 1 report. Geneva: World Health Organization; 2016 (WHO Technical Report Series, No.  
2 999:7–8  
3 [http://www.who.int/biologicals/expert\\_committee/WHO\\_TRS\\_999\\_corrigena\\_web.pdf?ua=1](http://www.who.int/biologicals/expert_committee/WHO_TRS_999_corrigena_web.pdf?ua=1),  
4 accessed 17 May 2018).
- 5 10. Report on the expert consultation on improving access to and use of similar  
6 biotherapeutic products, Geneva, Switzerland, 2–3 May 2017. Geneva: World Health  
7 Organization; 2017  
8 ([http://www.who.int/medicines/access/biotherapeutics/FINAL\\_Report-improving-  
9 access-to-and-use-of-biotherapeutics\\_October2017.pdf](http://www.who.int/medicines/access/biotherapeutics/FINAL_Report-improving-access-to-and-use-of-biotherapeutics_October2017.pdf) , accessed 19 July 2018).
- 10 11. IPRF Biosimilars Working Group. Reflection paper on extrapolation of indications in  
11 authorization of biosimilar products. International Pharmaceutical Regulators  
12 Forum; 2017  
13 ([https://www.i-p-r-  
14 f.org/files/6715/1012/3262/Final\\_BWG\\_Reflection\\_paper\\_Biosimilar\\_Extrapolation  
15 Final\\_clean\\_version\\_17.9.25.pdf](https://www.i-p-r-f.org/files/6715/1012/3262/Final_BWG_Reflection_paper_Biosimilar_Extrapolation_Final_clean_version_17.9.25.pdf), accessed 10 May 2018).

16  
17

===

DRAFT